ESMO26: Toni Choueiri, MD on LITESPARK-012 - Takeaways - MDSpire
Coming Soon: Introducing MDSpire News. Learn more
Conexiant’s news site is now MDSpire News. Learn more

ESMO26: Toni Choueiri, MD on LITESPARK-012

  • November 17, 2026

Share

  • 1

    Toni Choueiri, MD, presented results from LITESPARK-012 at ESMO26.

  • 2

    LITESPARK-012 was the first study of a triplet combination in advanced kidney cancer.

  • 3

    The triplet combination did not improve efficacy.

  • 4

    Choueiri described the results as surprising.

  • 5

    Choueiri said the findings are important for informing future studies.

Original Source(s)

Related Content